Your session is about to expire
← Back to Search
AZD9150 + Durvalumab and Chemotherapy for Solid Cancers
Study Summary
This trial is testing a new drug, AZD9150, to see if it is safe and works well against cancer. The trial will first test AZD9150 alone and then in combination with another drug, durvalumab, or with chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken immunosuppressive drugs in the last 14 days.I am using herbal preparations.I have brain metastases or spinal cord compression but haven't needed steroids for 14 days.You have had bad allergic reactions to the study drugs or other chemotherapy drugs in the past.I agree to give a sample for genetic testing and research.My blood tests show my organs and bone marrow are not working well.I have not had a live vaccine in the last 28 days.I do not have severe diseases or uncontrolled conditions.I have a confirmed solid tumor cancer, not liver cancer, with no effective standard treatment left.I am willing to have a biopsy for the study, unless I'm in the first 3 of any arm or in Part D.My cancer does not respond to standard treatments anymore.I have a tumor that can be measured and has not been treated with radiation.I am not pregnant, not breastfeeding, and either use birth control or cannot become pregnant.I have or had lung inflammation treated with steroids.You have a history of a weak immune system from birth.Your heart's electrical activity (measured by QT interval) is too long during rest.I am a male and either surgically sterile or using contraception during and for 20 weeks after the study.I do not have an active infection, including tuberculosis.I am 18 years old or older.I am currently receiving treatment for cancer.You are expected to live for at least 12 weeks.I have side effects from previous treatments that are not severe.I am fully active or restricted in physically strenuous activity but can do light work.
- Group 1: Arm D: AZD9150 IV
- Group 2: Arm A4
- Group 3: Arm A5
- Group 4: Arm D: AZD9150 SC
- Group 5: Arm A1
- Group 6: Arm A2
- Group 7: Arm A3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How hazardous is AZD9150 to patient health?
"Our team has assigned AZD9150 a rating of 1 on the safety scale, as this drug is currently under evaluation in Phase 1 trials and there is only limited data available to support both its efficacy and security."
What is the current geographic scope of this research endeavor?
"This medical study is actively enrolling participants from 6 sites, including Fairfax, Oklahoma City and Dallas. To reduce hardship for any potential volunteers, it may be best to choose a clinic that's close by."
Are there currently any opportunities for volunteers to join this experiment?
"Currently, this clinical trial is not open for recruitment. It was initially posted on February 7th 2018 and its last update was November 2nd 2022. If you are seeking other research opportunities, there are 3671 studies searching for cancer patients and 1916 trials requiring AZD9150 participants."
What ailments is AZD9150 traditionally used to address?
"AZD9150 is a medication utilized to treat metastatic ureter urothelial carcinoma, lymphoma, advanced non-small cell lung cancer and more. It has also been used for initial treatments of certain conditions."
What are the chief aims of this research?
"The primary outcome of this trial is to assess the minimum plasma concentration at steady state [Ctrough (ss)] of AZD9150 when administered in combination with durvalumab. Blood samples for PK analysis will be collected over a time frame spanning Weeks 0, 1, 5, 6 and 9. Secondary objectives include determining systemic clearance [CL(ss)], area under the plasma concentration versus time curve [AUC(0-inf)], as well as injection site tolerability when compared against intravenous administration QW in conjunction with durvalumab Q4W."
What prior investigations have there been into the efficacy of AZD9150?
"AZD9150 was initially studied at City of Hope Comprehensive Cancer Centre in 1997. As of now, 2866 trials have been finished and 1916 are still recruiting participants - the majority being conducted out of Fairfax, Virginia."
Does this experiment accommodate those aged 80 or above?
"This research initiative is recruiting patients that are aged 18 years or older, and no more than 130."
To what extent is participant recruitment for this experiment progressing?
"This study is no longer welcoming applications. It was originally posted on February 7th 2018 and the last update to its status occurred in November 2nd 2022. Nonetheless, individuals with cancer can still explore 3671 clinical trials currently recruiting participants, as well as 1916 studies enrolling people for AZD9150."
Share this study with friends
Copy Link
Messenger